JHM is committed to becoming
a global leader in synthetic biology
Continuously broadening the applications of recombinant protein drugs and products in consumer healthcare and therapeutic solutions thereby creating exceptional value for human health.
Learn More
JHM is committed to becoming
a global leader in synthetic biology
Continuously broadening the applications of recombinant protein drugs and products in consumer healthcare and therapeutic solutions thereby creating exceptional value for human health.
Learn More
JHM Biopharmaceutical (Hangzhou) Co., Ltd.(hereinafter referred to as "JHM") is a business dedicated to the development and commercialization of innovative synthetic biology products and technologies. JHM is committed to advancing the use of innovative recombinant protein drugs in endocrine therapy, neurotherapy, anti-aging skincare, and other next-generation biomedical material applications. Our mission is to provide groundbreaking biopharmaceutical products and treatments to patients worldwide.
JHM adheres to a patient-centered approach, driven by technological innovation. The company focuses on both consumer healthcare and therapeutic solutions., accelerating the development of its product pipeline and striving for industry leadership in the field of recombinant protein drugs.
Learn More
JHM Biopharmaceutical (Hangzhou) Co., Ltd.(hereinafter referred to as "JHM") is a business dedicated to the development and commercialization of innovative synthetic biology products and technologies. JHM is committed to advancing the use of innovative recombinant protein drugs in endocrine therapy, neurotherapy, anti-aging skincare, and other next-generation biomedical material applications. Our mission is to provide groundbreaking biopharmaceutical products and treatments to patients worldwide.
JHM adheres to a patient-centered approach, driven by technological innovation. The company focuses on both consumer healthcare and therapeutic solutions., accelerating the development of its product pipeline and striving for industry leadership in the field of recombinant protein drugs.
Dr. Leng Chunsheng, Founder
Learn More
Our News
JHM Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
Learn More
JHM Raises Nearly CN¥350 million in Series B and B+ Financing
Learn More
JHM Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
Learn More
Our News
2024-09-14
JHM Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
Learn More
2024-09-10
JHM Raises Nearly CN¥350 million in Series B and B+ Financing
Learn More
2024-06-27
JHM Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
Learn More